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RÉSUMÉ 
Impact du diagnostic psychiatrique sur les prescriptions d'antipsychotiques 
Ce travail s'inscrit dans un programme de recherche centré sur la pharmacovigilance en 
psychiatrie. 
Buts de l'étude 
Les nouveaux antipsychotiques atypiques sont prescrits avec beaucoup de succès, parce 
qu'ils présentent une sécurité dans leur emploi bien supérieure à celle des antipsychotiques 
classiques. Cette situation a conduit à une large prescription « off-label » (hors indication 
admise). Le but de ce trava.il a été d'étudier la pratique en matière de prescription des 
psychiatres hospitaliers en ce qui concerne les antipsychotiques en comparant des patients 
traités pour des psychoses ou d'autres indications officielles aux patients recevant un 
traitement antipsychotique « off-label ». 
Méthode 
Dans le cadre d'un programme de pharmacovigilance - pharmacoépidemiologie, tous les 
médicaments prescrits à 5 jours de référence (entre 1999 et 2001) à l'hôpital psychiatrique 
universitaire de Lausanne (98 lits) ont été enregistrés, avec des données sur l'âge, le sexe 
et le diagnostic des patients. Les prescriptions de 202 patients ont été évaluées . 
. Les patients ont été classés dans 3 groupes diagnostiques : (1) patient présentant des 
troubles psychotiques, (2) patient présentant des épisodes maniaques et des épisodes 
dépressifs avec des symptômes psychotiques, et (3) patient présentant d'autres troubles. 
Les groupes (1) et (2) forment une classe de patients recevant un antipsychotique pour une 
indication officielle, et les prescriptions dans le groupe (3) ont été considérées comme « off-
label ». 
Résultats principaux 
Moins de patients psychotiques ont reçu un antidépresseur (p<0.05) ou des hypnotiques 
non-benzodiazepine (p<0.001) comparés aux patients des deux autres groupes. Les patients 
présentant des troubles affectifs recevaient seulement exceptionnellement une combinaison 
d'un antipsychotique atypique et conventionnel, tandis qu'un nombre inférieur de patients 
avec des indications « off-label » ont reçu moins souvent des antipsychotiques atypiques 
que ceux des deux groupes de comparaison (p<0.05). L'analyse statistique (stepwise logistic 
regression) a révélé que les patients présentant des troubles psychotiques avaient un risque 
plus élevé de recevoir un médicament antipsychotique d'une dose moyenne ou élevée, 
(p<0.001) en comparaison aux deux autres groupes. 
Conclusion 
Les nouveaux médicaments antipsychotiques semblent être prescrits avec moins d'hésitation 
principalement pour des indications admises. Les médecins prescrivent de nouveaux 
médicaments « off-label » seulement après avoir acquis une certaine expérience dans le 
domaine des indications approuvées, et ils étaient plus prudents en ce qui concerne la dose 
en traitant sur la base « off-label ». 
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Abstract 
Objective 
The new brands of atypical antipsychotics are very successfully prescribed because 
of their enhanced safety profiles and their larger pharmacological profile in 
comparison to the conventional antipsychotic. This has led to broad off-label 
utilisation. The aim of the present survey was to study the prescription practice of 
hospital psychiatrists with regard to antipsychotic drugs, comparing patients treated 
for psychoses or other registered indications to patients receiving an off-label 
antipsychotic treatment. 
Method 
As part of a pharmacovigilance/pharmacoepidemiology program, all drugs given on 5 
reference days (1999 - 2001) in the 98-bed psychiatrie hospital of the University of 
Lausanne, Switzerland, were recorded along with age, sex and diagnosis. The 
prescrrptions of 202 patients were assessed. 
Patients were classified in 3 diagnostic groups: (1) patient with psychotic disorders, 
(2) patients with manie episodes and depressive episodes with psychotic symptoms, 
and (3) patients with other disorders. Group (1) and (2) formed the class of patients 
receiving an antipsychotic for a registered indication, and the prescriptions in group 
(3) were considered as off-label. 
Main results 
A lesser number of psychotic patients received antidepressant (p<0.05) and 
nonbenzodiazepine hypnotics (p<0.001) compared to the patients of the other two 
groups. The patients with affective disorders received only exceptionally a 
combination of an atypical and a conventional antipsychotic, whereas a lesser 
number of patients with off-label indications received less often atypical 
antipsychptics than those of the two comparison groups (p<0.05). Stepwise logistic 
regression revealed that patients with psychotic disorder were at higher risk of 
receiving an antipsychotic medication in medium or high dose (p<0.001 ), in 
comparison to the two other groups. 
Conclusions 
The new antipsychotic drugs seem to be prescribed with less hesitation mainly for 
approved indications. Physicians prescribe new drugs on off-label application only 
after having gained some experience in the field of the approved indications, and 
were more cautious with regard to dose when treating on an off-label basis. 
Key words 
Antipsychotic drugs, off-label use, prescription habits, psychotic disorders, affective 
disorders 
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OFF-LABEL UTILIZATl.ON OF ANTIPSYCHOTICS 
Introduction 
There has been recently an increasing interest to understand the factors that 
influence the prescription of psychotropic drugs. Characteristics of the health care 
system, physician management style, physician specialty and training, public 
attitudes, drug cost and availability, patients preferences, local education tradition, 
marketing and formulary have been reported to have some impact on prescription 
habits 1-5 . On the other hand, it is reported that the patient' characteristics were taken 
less into consideration when physicians prescribe for adult patients 3· 4 . 
A major concern in studies on drug utilisation during the ?Os and 80s was the 
appropriateness of the practices of psychotropic drug prescription 4. Many articles on 
this tapie pointed out the frequent lack of concordance between psychiatrie 
diagnoses and the prescribed psychotropic medications 6• 7 , i.e. and they revealed 
their off-label use. · 
This may be particularly true with antipsychotic medications, due in part to their 
sedative properties, frequently used without a need of antipsychotic effect 8 . 
The arrivai of the newer atypical antipsychotics has achieved rapid acceptance by 
prescribers because of enhanced safety profiles, relative to those observed with 
conventional antipsychotics 9. Besides their evident antipsychotic efficacy, they have 
been found to offer a larger pharmacological profile than conventional antipsychotic 
10
, with some efficacy in depressive and anxious symptoms as well as suicide 
prevention and in mood stabilization. This has, combined with the favourable 
tolerance profile, led to broad off-label utilizations. 
Whereas several of the actual off-label utilizations are investigated with regard to 
their responsiveness to the newer antipsychotics, no conclusive data is often 
available with regard to the specific prescription modalities like dose, treatment 
duration, comedication, etc. 
The aim of the present survey is to study the prescription habits of hospital 
psychiatrists with regard to antipsychotic drugs, comparing patients treated for 
psychoses or other registered indications with patients receiving off-label 
antipsychotic treatment. 
Methods 
The present study has been realized as part of the AMSP project 
(Arzneimittelsicherheit in der Psychiatrie= drug safety in psychiatry), which is a 
program for continuous assessment of adverse drug reactions in psychiatrie 
inpatients under naturalistic conditions of routine clinical treatment. The methodology 
has been described elsewhere 11 -13 . Currently, more than 35 German and Swiss sites 
are participating. Data on drug use in the participating hospitals are based on two 
reference days per year. Ali drugs given on a reference day are recorded along with 
age, sex, and diagnosis (ICD-10) for ail patients under surveillance. The daily dosage 
is also recorded. 
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The data of the present study are drawn out of 5 reference days from 1999 to 2001 in 
the 98-bed psychiatrie hospital of the University of Lausanne, Switzerland. Presently 
the mean hospitalisation duration is 20 days and the nurse/bed ratio is 0.95. 
Definition of drug classes 
The group of atypical antipsychotics was defined as including clozapine, olanzapine, 
risperidone, quetiapine and amisulpride. Ali other antipsychotics were classed as 
conventional antipsychotics. 
Among the conventional antipsychotics, two subclasses were identified: "sedative" 
and "high potency". Sedative antipsychotics were levomepromazine, promazine, 
clotiapine, thioridazine, and chlorprotixen. High potency antipsychotics were 
zuclopentixol, haloperidol, penfluridol, flupentixol and fluphenazine. 
Benzodiazepines were classified as one group, including sedative and hypnotic 
drugs. As sedative benzodiazepines were also often used as hypnotics, the different 
indications therefore being difficult to assess. Nonbenzodiazepine hypnotics formed a 
further drug class, including zolpidem, zopiclone and zaleplon. Further classified 
were anticonvulsants, lithium salts, anticholinergics, and somatic drugs. 
Three antipsychotic drug dose ranges were defined (see Table 1). 
Wards 
Data on prescriptions was collected in 5 different wards. Two of these wards are 
specialized in the treatment of patients presenting a diagnosis of the schizophrenia 
spectrum disorders and are supervised by the same senior physicians. Two wards 
are aimed of treating anxiety and affective disorders, bath again run by the same 
team of physicians. The fifth ward treats particularly patients with cluster B and C 
personality disorders. 
Analyses 
ln descriptive data analyses, means and standard deviations were calculated for 
numerical variables while frequency categories values and percentages are reported 
for nominal variables. ln exploratory analyses, the differences between groups were 
tested with chi-square tests (for nominal variables) and analyses of variance for 
numerical ones. 
Three predictive models were built with multivariate logistic regression analysis. 
Stepwise binary logistic regression analysis was used to determine factors predicting 
the prescription of atypical antipsychotics and the prescription of benzodiazepines. 
The forward stepwise method using likelihood-ratio statistic was performed. The third 
model, predicting the antipsychotic dose range used was analysed by stepwise 
multinominal logistic regression. Multinominal logistic regression broke the regression 
up into a series of binary regressions comparing each group to a baseline group, 
which we determined to be the low dose range group. 
The data were analysed using the SPSS for Windows program, version 12.0. 
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Results 
Characteristics of the sample 
The prescriptions of 202 patients were assessed. The mean (± SD) age was 38.6 ± 
12.2 (range 18 - 64 ). The proportion of women was 43.1 %. There were no 
differences between index days with regard to age and sex distribution. 
The distribution regarding their primary ICD-10 diagnosis was: Mental and 
, behavioural disorders due to psychoactive substance use (F10): 9 (4.5 %); 
Schizophrenia, schizotypal and delusional disorders (F20): 122 (60.4 % ); Mood 
disorders (F30): 39 (19.3 %); Behavioural syndromes associated with physiological 
disturbances and physical factors (F50): 6 (3.0 %); Disorders of adult personality and 
behaviour (F60): 24 (11.9 %). 
Number of prescribed drugs per patient and comedications 
The mean number of drugs administered was 4.0 ± 1.8 (range 1 - 10), and the mean 
number of prescribed antipsychotics was 1.3 ± 0.5 (range 1 - 3). 
Fifty patients received nonbenzodiazepine hypnotics (24.8 %), 117 (57.9 %) had 
benzodiazepines prescribed, 70 (34.7 %) antidepressants, 38 (18.8 %) 
anticonvulsants, 28 (13.9 %) lithium, 54 (26.7 %) anticholinergics, and 83 (41.1 %) 
somatic drugs. 
Atypica/ vs. conventiona/ antipsychotics 
Patients treated with atypical antipsychotics (n = 67) were compared to those 
receiving conventional antipsychotics (n = 99), subjects being prescribed drugs from 
bath classes forming a third group (n = 36). There was no difference with regard to 
age and sex between the three groups. As expected, the mean number of drugs was 
different between the first two groups (atypical or conventional antipsychotic) and the 
third group (combination): 3.6 ± 1.7, 3.9 ± 1.7 and 4.8 ± 1.8 respectively (p < 0.01 ). 
The same was true for the mean number of antipsychotics per patient: for patients 
with atypical antipsychotics 1.0 ± 0.1, for those with conventional drugs 1.3 ± 0.5, and 
for those with a combination of bath 2.1 ± 0.2 (p < 0.001 ). No differences were found 
with regard to number of comedications: atypical antipsychotics 2.6 ± 1. 7, 
conventional antipsychotics 2.6 ± 1.8, combination 2.8 ± 1.8. 
The proportion of patients treated concomitantly with different substance classes are 
shown in Table Il. Patients treated with conventional antipsychotics received less 
antidepressants (p < 0.05), whereas patients under atypical antipsychotics were less 
likely to receive anticholinergics (p < 0.01 ). Two observations may be of particular 
interest: Twelve percent of patients under atypical antipsychotics had a concomitant 
anticholinergic treatment, and patients under an "atypical/conventional combination" 
treatment presented a similar proportion of anticholinergic treatment. 
The distribution with regard to dose ranges showed significant differences between 
the three groups. Patients treated with atypical antipsychotics received mainly 
medium doses, patients treated with combination of bath antipsychotic classes 
mostly high doses, whereas the group receiving conventional drugs was more evenly 
distributed (p < 0.001 ). 
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Diagnostic groups and prescription habits 
Patients were classified in 3 diagnostic groups: (1) patient with F20 (psychotic 
disorders) diagnoses, (2) patients with manie episodes (F30.x, F31.1, F31.2) and 
depressive episodes with psychotic symptoms (F32.3, F33.3), and (3) patients with 
other disorders. Group (1) and (2) formed the class of patients receiving an 
antipsychotic for a registered indication, and the prescriptions in group (3) can be 
considered as off-label. 
The 3 groups differed with regard to age [F(2)=6.12; p=0.003]: psychotic patients 
37.7 ± 11.8 years, patients with affective disorders 44.4 ±13.9 years, patients with off-
label indications 35.7 ± 9.9 years. The contrasts between patients with registered 
indication vs. patients with off-label indications was significant [t(199)=2.45; p=0.015], 
whereas the contrast between psychotic patients vs. the other two diagnostic 
categories was not [F(199)=-1.38; p=0.169]. 
As shown in Table Ill, the diagnostic groups differed with regard to number of 
prescribed drug per patient (p<0.01 ), number of prescribed antipsychotic per patient 
(p<0.001) and number of prescribed comedication drugs (p<0.001 ). Contrasting 
registered indications (groups 1 and 2) with off-label indications (group 3) revealed no 
significant differences with regard to these observations. Contrasting psychotic 
patients with the two other groups revealed significant differences for all 3 
comparisons (p<0.001 ). 
Several differences appeared between the diagnostic groups with regard to 
comedications: less psychotic patients received antidepressant (p<0.05) and 
nonbenzodiazepine hypnotics (p<0.001) than patients of the other two groups. More 
patients of the affective disorders group received anticonvulsants than subjects of the 
two comparative groups (p<0.001 ). 
Patients with affective disorders received only exceptionally a combination of an 
atypical and a conventional antipsychotic, whereas patients with off-label indications 
received less often atypical antipsychotics than the two comparison groups (p<0.05). 
Secular effects 
Only one significant change over the 5 index days was observed. The percentage of 
patients treated with atypical antipsychotics increased over the observation period. 
The proportions for the 5 index days were 25.5%, 22.5%, 29.4%, 33.3% and 53.3% 
respectively, the differences being statistically significant (p < 0.05). 
As shown in Figure 1, there is a secular trend which can be found for patients without 
psychosis, who were less often be treated with atypical antipsychotics than patients 
with·the diagnosis of psychosis, at the beginning of the observation, the difference 
disappearing untîl the last observation. 
Logistic regressions 
Three predictive models were built with multivariate logistic regression analysis. 
A first model was computed to determine factors predicting the prescription of 
atypical antipsychotics (Table IV). The following parameters were entered into the 
stepwise logistic regression model: index day, sex, age, diagnostic class, and use of 
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nonbenzodiazepine hypnotics, benzodiazepines, antidepressants, anticonvulsants, 
lithium and somatic drugs. The parameters diagnostic class and prescription of an 
antidepressant were retained. The positive predictive value was 57.8%. 
The second model was aimed to determine factors predicting the prescription of 
concomitant benzodiazepines (Table V). The parameters entered into the stepwise 
logistic regression model were: index day, sex, age, diagnostic class, and use of an 
atypical antipsychotic, of nonbenzodiazepine hypnotics, antidepressants, 
anticonvul.sants, lithium and somatic drugs. The parameters retained were the use of 
antidepressants and the use of nonbenzodiazepine hypnotics. The positive predictive 
value was 62.3%. 
Stepwise multinominal logistic regression analysis was used to assess factors 
associated with the use of medium range and high range doses (Table VI). The 
group of individuals having received the antipsychotic medication at a low dose range 
were defined as the reference group. The following parameters were entered into the 
mode!: age, index day, sex, diagnostic class, use of nonbenzodiazepine hypnotics, 
benzodiazepines, antidepressants, anticonvulsants, lithium, antiparkinsonians, and 
somatic drugs. The parameters of the diagnostic class and the preseription of 
antiparkinsonian drugs were retained. The positive predictive value was 50.5%. 
Presenting a primary diagnosis of a ICD-1 O:F20 disorder was associated with a 10-
fold risk of having received the antipsychotic medication in the middle dosage range 
and not in the low dosage range (p<0.001 ), and a 20-fold risk of receiving 
antipsychotics in the high dose range (p<0.001 ). For patients with an affective 
disorder considered a registered indication for an antipsychotic treatment, the odds 
ratio of receiving a middle dose treatment was 4.75 (p<0.05), but the increased 
relative risk to receive a high dose therapy instead of a low-dose treatment was not 
significant. Whereas patients treated on an off-label basis did not have a significantly 
higher risk to receive a middle dose treatment compared to a low dose regimen, their 
odds ratio of receiving their antipsychotics in high doses was 7.77 higher than for low 
doses (p<0.007). When patients received an antiparkinsonian, the risk that they also 
were treated with high antipsychotic doses was increased 8.29-fold compared to low 
doses (p<0.01 ). 
Discussion 
Like in previous survey studies in psychiatrie hospitals 14-18 , polypharmacy was 
frequent in our sample, the mean number of prescribed drugs being 4 and ranging 
from 1 to 10 drugs per patient. Whereas polypharmacy has often been considered as 
malpractice in earlier studies 19-22 , it has become increasingly apparent nowadays, 
that psychiatrie polypharmacy can have some advantages, i.e. to further improve 
sleep, have a more patent anxiolytic or sedative effect and to overcome therapy 
resistances 17• 23• 24 . Such considerations may also have played a role for the 
prescription habits of the physicians in our study, as 58% of the patients in our 
sample received benzodiazepines concomitantly to the antipsychotic, and 25% a 
nonbenzodiazepine hypnotic. This seemed to be particularly true for patients with 
affective or other disorders, as psychotic patients received less comedications in 
general and especially less antidepressant and nonbenzodiazepine hypnotics. 
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lnterestingly, conventional antipsychotics were more often associated with an 
antidepressant comedication. This may be due to differences between the two 
diagnostic classes with regard to secular trends. The use of newly introduced atypical 
antipsychotic drugs spread more rapidly in the treatment of psychoses (the primary 
indication), and with certain latency in pharmacotherapy of affective disorders (mania 
and psychotic depression) and off-label indications. 
Whereas patients with the diagnosis of a psychosis were already treated in more 
than 50% of the cases with an atypical agent at the beginning of the observation 
period, the proportion was 25% in patients without psychosis. The difference 
vanished over the five index days, the proportion of prescribed atypical antipsychotics 
being near 65% in ail diagnostic groups during the last index day. The most 
convincing hypothesis rationalizing these observations would be that the newer drugs 
were used with less hesitations firstly in approved indications, and that prescribing 
physicians used newer drugs off-label only after having accumulated some 
experience in approved indications. This effect may even have been reinforced by 
the fact, that our hospital wards are organized according to diagnostic groups 
(schizophrenia, affective disorders, personality disorders, triage unit). Therefore 
physicians working in the units with a high prevalence of psychotic patients had 
accumulated experiences with newer drugs more rapidly. One can, furthermore, 
hypothesize that due to the usual turn-over of the assistants (residents) the 
prescribing habits developed on the specialised wards was "exported" later on in the 
whole hospital. 
Further interesting results are the dose differences between patients treated for an 
approved indication compared to off-label use. Whereas the proportion of patients 
being treated with antipsychotics at medium doses was similar, high doses were 
more frequent in patients with approved indications, low doses were more frequent 
for off-label use. Once again, physicians treating patients with approved indications 
seem to be less hesitant when using antipsychotics. 
The observations made with regard to comedications confirmed what was expected. 
Antidepressants, nonbenzodiazepine hypnotics and mood stabilizers were more 
often given to patients without psychosis, most likely in order to treat their primary 
disease, using antipsychotics probably most often as sedatives. 
The use of atypical antipsychotics itself seems to be associated with some particular 
prescribing habits. As cou Id be expected, the use of anticholinergics was lower. 
Atypical drugs were particularly often been used in medium doses, whereas 
monotherapy with conventional drugs was also in more than one third of the cases 
been applied in higher doses. This last observation is difficult to interpret. One highly 
speculative hypothesis could be that the prescribing physicians were more confident 
in the effects of atypical antipsychotics, using them less often in high doses. 
The results of this study need to be viewed against their methodological limitations. 
The data are based on five index day surveys, i.e. five crossover data samples. The 
secular trends found in this study should therefore be interpreted with particular 
caution. Furthermore, the measured data do not always reflect the intended 
medication for one given patient, which is a more dynamic process. This will be 
particularly the case in patients having been hospitalised only recently, whose 
medication is possibly not yet stabilized. The diagnoses were derived from the 
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medical records, could therefore not be considered as valid as diagnoses which 
would have been determined by structured interviews. 
Whereas previous studies have stressed out that prescription habits are primarily 
influenced by doctors characteristics and contextual factors 1•5 , less likely by patients 
characteristics 3· 4 , our study suggests that, at least shortly after the introduction of 
newer therapeutic agents, patients diagnosis may influence drug choice, dose and 
comedications. While no analogous data on off label prescribing has been published, 
to our knowledge, in Africa, it seems likely that similar observation may be made in 
the South African context. 
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Figure 1 
Evolution of the proportion of atypical antipsychotics over the five 
index days of the study: comparison between the 3 diagnostic 
groups 
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Table 1 
Defined dose ranges for antipsychotic drugs 
Dose 
low medium high 
Levomepromazine < 100 100-200 >200 
risperidone <3 3-4 >4 
olanzapine <10 10-20 >20 
clozapine <200 200-400 >400 
clotiapine <80 80-120 >120 
clopentixol <20 20-40 >40 
haloperidol <6 6-10 >10 
penfluridol <20/week 21-40 >40 
chlorprothixen <45 45-90 >90 
flupentixol <4 4-6 >6 
quetiapine <300 300-600 >600 
fluphenazin <20 20-50 >50 
thioridazin <100 100-200 >200 
amisulprid <300 300-600 >600 
Table Il 
Comparison of patients treated with atypical antipsychotics with those treated with conventional antipsychotics 
Atypical Conventional . Both 
(n = 67) (n = 99) (n = 36) 
Comedication {drug c/ass) 
Antidepressants 40.3 % 26.3 % 47.2 % Chi2 (2)=6.55 * 
Benzodiazepines 64.2 % 51.5 % 63.9 % Chi2 (2)=3.27 ns 
Hypnotics 20.9 % 26.3 % 27.8 % Chi2 (2}=0.83 ns 
Anticonvulsants 17.9 % 22.2 % 11.1 % Chi2 (2)=2.19 ns 
Lithium 14.9 % 15.2 % 8.3 % Chi2 (2)=1.12 ns 
Anticholinergics 11.9 % 34.3 % 33.3 % Chi2 (2)=11.21 ** 
Somatic drugs 43.3 % 38.4 % 44.4 % Chi2 (2)=0.60 ns 
Antipsychotic dose received 
Dose range 
Low 16.4 % 22.2 % 2.8 % Chi2 (4 )=60.92 *** 
Medium 71.6 % 42.4 % 11.1 % 
High 11.9 % 35.4 % 86.1 % 
Table Ill 
Diagnostic groups and prescription habits 
Psychosis Labelled Off label Contrast registered indications vs off-label use Contras! Psychosis vs others 
(n = 80) affective indication 
· disorder (n =51) 
(n = 122) 
p 
mean SD mean SD mean SD 
Number drugs 3.54 1.61 4.79 1.64 4.39 1.95 F(2)=9.84 0.003 !(199)=-0.726 0.469 !(199)=-4.324 <0.001 
Number Antipsychotics 1.43 0.56 1.05 0.32 1.22 0.47 F(2)=9.01 <0.001 !(199)=0.210 0.834 !(199)=-4.002 <0.001 
Number Comedication 2.11 1.53 3.74 1.63 3.17 1.82 F(2)=17.89 <0.001 !(199)=-0.828 0.409 t(199)=-5.706 <0.001 
Comedication (drug c/ass) 
Antidepressants 27.9 % 41.0 % 48.8 % ChQ (2)=6.79 0.034 
Benzodlazepines 54.9 % 64.1 % 61.0 % Ch12 (2)=1.22 0.543 
Hypnotics 18.0 % 38.5 % 31.7 % Ch12 (2)=7.96 0.019 
Anticonvulsants 11.5 % 41.0 % 19.5 % Ch~ (2)=16.91 <0.001 
Lithium 7.4 % 41.0 % 7.3 % Ch~ (2)=29.87 <0.001 
Anticho!inergics 30.3 % 30.8 % 12.2 % ChQ (2)=5.55 0.062 
Somalie drugs 36.1 % 51.3 % 46.3 % Ch~ (2)=3.41 0.182 
Glass of antipsychotics 
Alypical 35.2 % 35.9 % 24.4 % ChQ(4)=11.41 0.022 
Conventional 41.8 % 61.5 % 58.5 % 
Bo th 23.0 % 2.6 % 17.1 % 
Proportion hifh-potency (N Conventionals = 133) 65.4 % 72.0 % 20.0 % Ch~ (2)=2120 <0.001 
Proportion low-potency (N Conventionals = 133) 56.4 % 32.0 % 83.3 % Ch12 (2)=14.91 <0.001 
Dose range 
Law 9.2 % 28.0 % 30.0 % Ch~(4)=15.54 0.004 
Medium 28.9 % 48.0 % 30.0 % 
High 61.8 % 24.0 % 40.0 % 
Table IV 
Stepwise logisticregression mode! for use of atypical antipsychotics 
Diagnostic class 
Psychosis 
Registered affective disorder 
Off ~label use 
Use of an antidepressant 
Atypical antipsychotics 
OR8 p Cl 
0.38 
0.45 
2.73 
0.007 
0.010 
0.029 
0.001 
0.18 - 0.79 
0.22 - 0.92 
1.51 - 4.92 
a Odds ration for the probability of receiving an atypical antipsychotic 
Table V 
Stepwise logistic regression mode! for use of benzodiazepines 
OR8 
Use of an antidepressant 2.50 
. Use of a nonbenzodiazepine hypnotic 1.97 
Benzodiazepines 
p 
0.002 
0.049 
a Odds ration for the probability of receiving a benzodiazepine 
Cl 
1.40 - 4.44 
1.00 - 3.85 
Table VI 
Logistic regression mode! for choice of antipsychotic dose range 
Medium dosis High dosis 
OR p Cl OR p Cl 
Diagnostic class 
Psychotic 10.11 0.001 2.69 -38.08 20.66 <0.001 5.49 - 77.84 
Registered affective disorder 4.75 0.020 1.27-17.69 2.40 0.239 0.56 - 10.27 
Off-label indication 3.94 0.068 0.91 - 17.10 7.77 0.007 1.74 - 34.69 
Antiparkinsonian 2.89 0.113 0.78 - 10.72 8.29 0.002 2.18-31.46 
